SB
SAGE

Suntrust Banks’s Sage Therapeutics SAGE Stock Holding History

Suntrust Banks’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$801K Buy
5,714
+505
+10% +$84.5K ﹤0.01% 808
2019
Q2 		$953K Buy
5,209
+1,291
+33% +$220K 0.01% 793
2019
Q1 		$623K Buy
+3,918
New +$567K ﹤0.01% 890

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Suntrust Banks's SAGE Position: Q3 2019 in Review

Suntrust Banks increased its Sage Therapeutics (SAGE) stake by 9.7% in Q3 2019, buying an estimated $84.5K and bringing the position to 5,714 shares worth $801K. The position accounts for ﹤0.01% of the portfolio, ranked #808.

Suntrust Banks first reported a position in SAGE in Q1 2019 and has held it in 3 quarters since. The position peaked at $953K in Q2 2019. 285 funds tracked by Wall St. Rank hold SAGE as of Q3 2019.

  • Suntrust Banks held 5,714 shares of Sage Therapeutics worth $801K as of Q3 2019.
  • Suntrust Banks bought 505 Sage Therapeutics shares in Q3 2019, an estimated $84.5K.
  • Sage Therapeutics made up ﹤0.01% of Suntrust Banks's portfolio in Q3 2019, its #808 holding.
  • Suntrust Banks first reported a position in Sage Therapeutics in Q1 2019 and has held it in 3 quarters since.
  • Suntrust Banks's Sage Therapeutics position peaked at $953K in Q2 2019.
  • 285 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2019.

Based on Suntrust Banks's 13F filing for Q3 2019, filed 12 Nov 2019.